User:Mr. Ibrahem/Pirtobrutinib

Pirtobrutinib, sold under the brand name Jaypirca, is a medication used to treat mantle cell lymphoma (MCL). It is used when other treatments fail. It is taken by mouth.

Common side effects include tiredness, musculoskeletal pain, diarrhea, swelling, shortness of breath, pneumonia, and bruising. Laboratory abnormalities may include low neutrophils, low lymphocytes, or low platelets. Other side effects may include atrial fibrillation and other cancers. Use in pregnancy may harm the baby. It works to inhibit lymphocytes by blocking Bruton's tyrosine kinase (BTK).

Pirtobrutinib was approved for medical use in the United States in 2023. In Europe conditional approval was recommended in 2013. In the United States it costs about 22,000 USD per month as of 2023.